← Back to Screener
Nuvalent, Inc. Class A Common Stock (NUVL)
Price$108.24
Favorite Metrics
Price vs S&P 500 (26W)13.40%
Price vs S&P 500 (4W)4.06%
Market Capitalization$8.46B
All Metrics
Book Value / Share (Quarterly)$15.96
P/TBV (Annual)8.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.52
Price vs S&P 500 (YTD)2.84%
EPS (TTM)$-5.85
10-Day Avg Trading Volume0.53M
EPS Excl Extra (TTM)$-5.85
EPS (Annual)$-5.85
ROI (Annual)-34.08%
Cash / Share (Quarterly)$17.54
ROA (Last FY)-30.11%
EBITD / Share (TTM)$-6.46
ROE (5Y Avg)-22.08%
Cash Flow / Share (Annual)$-3.52
P/B Ratio6.78x
P/B Ratio (Quarterly)5.86x
Net Income / Employee (Annual)$-2
ROA (TTM)-37.49%
EPS Incl Extra (Annual)$-5.85
Current Ratio (Annual)15.27x
Quick Ratio (Quarterly)15.05x
3-Month Avg Trading Volume0.55M
52-Week Price Return53.79%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.93
52-Week High$113.02
EPS Excl Extra (Annual)$-5.85
26-Week Price Return22.15%
Quick Ratio (Annual)15.05x
13-Week Price Return-0.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.27x
Enterprise Value$8,198.231
Revenue / Employee (Annual)$0
Cash / Share (Annual)$17.54
3-Month Return Std Dev36.00%
Net Income / Employee (TTM)$-2
ROE (Last FY)-34.08%
EPS Basic Excl Extra (Annual)$-5.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.85
ROI (TTM)-42.07%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.17
Price vs S&P 500 (52W)18.70%
Year-to-Date Return6.98%
5-Day Price Return3.78%
EPS Normalized (Annual)$-5.85
ROA (5Y Avg)-20.58%
Month-to-Date Return5.04%
Cash Flow / Share (TTM)$-2.03
EBITD / Share (Annual)$-6.46
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-22.08%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.85
P/TBV (Quarterly)10.01x
P/B Ratio (Annual)5.86x
Book Value / Share (Annual)$15.96
Price vs S&P 500 (13W)-3.08%
Beta1.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-42.07%
52-Week Low$63.55
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NUVLNuvalent, Inc. Class A Common Stock | — | — | — | — | $108.24 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nuvalent is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors for patients with genetically defined cancers. The company's pipeline includes NVL-520 for ROS1-positive NSCLC, NVL-655 for ALK-positive NSCLC, and NVL-330, a brain-penetrant HER2-selective inhibitor designed to address limitations of existing targeted therapies. All operations are based in the United States.